Category C—May cause extrapyramidal and/or withdrawal symptoms in neonates with third trimester exposure
Lactation studies have not been conducted to assess the presence of asenapine in human milk
All atypicals may increase mortality in elderly patients by 1.7 times greater than placebo.
There are no dosage adjustments required
Contraindicated in patients with severe hepatic impairment; no dosage adjustment required in mild to moderate hepatic impairment